Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer and autoimmune ...

After withdrawing its initial filing last year, the immune drugmaker rebounded and added to a recent run of sizable new ...

Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's early-stage RNA ...

PathAI makes AI models that help with the analysis of patient tissue samples and diagnostic tools. Roche has partnered with ...

The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider ...

Avalo reported study success in what’s proven to be a tough-to-treat skin disease. Elsewhere, BioNTech announced plans to close multiple plants and Madrigal picked up an RNA-based drug for MASH.

A Series D round led by Venrock will support an ongoing Phase 2 study, and planned Phase 3 trial, of an oral drug the biotech ...

Bayer has agreed to acquire biotechnology startup Perfuse Therapeutics in a deal that could be worth up to $2.45 billion, marking the healthcare conglomerate’s first — and potentially largest — drug ...

Whereas earlier Phase 3 results disappointed Wall Street, new findings in people with “chronic” disease were viewed by ...

Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and ...

The British biotechnology startup is making "pan-gamma delta” T cell engagers it says can address the limitations of similar, ...

While overall revenue fell just shy of Wall Street forecasts, sales of the gene editing medicine Casgevy and pain drug ...